Impact of hormonal therapy on HIV-1 immune markers in cis women and gender minorities.
CD4 count
HIV‐1
HIV‐1 immune markers
cis women
sex hormone
trans women and non‐binary people
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
03 Jun 2024
03 Jun 2024
Historique:
received:
31
01
2024
accepted:
17
05
2024
medline:
4
6
2024
pubmed:
4
6
2024
entrez:
3
6
2024
Statut:
aheadofprint
Résumé
Although sex hormones are recognized to induce immune variations, the effect of hormonal therapy use on immunity is only poorly understood. Here, we quantified how hormonal therapy use affects HIV-1 immune markers in cis women (CW) and trans women and non-binary people (TNBP) with HIV. We considered CD4, CD8 and lymphocyte measurements from cis men (CM), CW and TNBP in the Swiss HIV Cohort Study. We modelled HIV-1 markers using linear mixed-effects models with an interaction between 'gender' (CW, TNBP) and 'hormonal therapy use' (yes/no). Models were adjusted on age, ethnicity, education level, time since start of antiretroviral therapy and use of intravenous drugs. We assessed the inflammatory effect of hormonal therapy use in 31 TNBP using serum proteomics measurements of 92 inflammation markers. We included 54 083 measurements from 3092 CW and 83 TNBP, and 147 230 measurements from 8611 CM. Hormonal therapy use increased CD4 count and CD4:CD8 ratio in TNBP more than in CW (p This study highlights the potential role of hormonal therapy use in modulating the immune system among other biological and social factors, especially in TNBP with HIV.
Sections du résumé
BACKGROUND
BACKGROUND
Although sex hormones are recognized to induce immune variations, the effect of hormonal therapy use on immunity is only poorly understood. Here, we quantified how hormonal therapy use affects HIV-1 immune markers in cis women (CW) and trans women and non-binary people (TNBP) with HIV.
METHODS
METHODS
We considered CD4, CD8 and lymphocyte measurements from cis men (CM), CW and TNBP in the Swiss HIV Cohort Study. We modelled HIV-1 markers using linear mixed-effects models with an interaction between 'gender' (CW, TNBP) and 'hormonal therapy use' (yes/no). Models were adjusted on age, ethnicity, education level, time since start of antiretroviral therapy and use of intravenous drugs. We assessed the inflammatory effect of hormonal therapy use in 31 TNBP using serum proteomics measurements of 92 inflammation markers.
RESULTS
RESULTS
We included 54 083 measurements from 3092 CW and 83 TNBP, and 147 230 measurements from 8611 CM. Hormonal therapy use increased CD4 count and CD4:CD8 ratio in TNBP more than in CW (p
CONCLUSION
CONCLUSIONS
This study highlights the potential role of hormonal therapy use in modulating the immune system among other biological and social factors, especially in TNBP with HIV.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Collegium Helveticum
Organisme : Swiss National Science Foundation
Pays : Switzerland
Organisme : Swiss HIV Cohort Study
Investigateurs
I Abela
(I)
K Aebi-Popp
(K)
A Anagnostopoulos
(A)
M Battegay
(M)
E Bernasconi
(E)
D L Braun
(DL)
H C Bucher
(HC)
A Calmy
(A)
M Cavassini
(M)
A Ciuffi
(A)
G Dollenmaier
(G)
M Egger
(M)
L Elzi
(L)
J Fehr
(J)
J Fellay
(J)
H Furrer
(H)
C A Fux
(CA)
H F Günthard
(HF)
A Hachfeld
(A)
D Haerry
(D)
B Hasse
(B)
H H Hirsch
(HH)
M Hoffmann
(M)
I Hösli
(I)
M Huber
(M)
D Jackson-Perry
(D)
C R Kahlert
(CR)
L Kaiser
(L)
O Keiser
(O)
T Klimkait
(T)
R D Kouyos
(RD)
H Kovari
(H)
K Kusejko
(K)
N Labhardt
(N)
K Leuzinger
(K)
B Martinez de Tejada
(B)
C Marzolini
(C)
K J Metzner
(KJ)
N Müller
(N)
J Nemeth
(J)
D Nicca
(D)
J Notter
(J)
P Paioni
(P)
G Pantaleo
(G)
M Perreau
(M)
A Rauch
(A)
L Salazar-Vizcaya
(L)
P Schmid
(P)
R Speck
(R)
M Stöckle
(M)
P Tarr
(P)
A Trkola
(A)
G Wandeler
(G)
M Weisser
(M)
S Yerly
(S)
Informations de copyright
© 2024 The Author(s). HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.
Références
Fink AL, Klein SL. The evolution of greater humoral immunity in females than males: implications for vaccine efficacy. Curr Opin Physio. 2018;6:16‐20.
Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and gender differences in the outcomes of vaccination over the life course. Annu Rev Cell Dev Biol. 2017;33(1):577‐599.
Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626‐638.
Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis. 2010;10(5):338‐349.
Lotter H, Altfeld M. Sex differences in immunity. Semin Immunopathol. 2019;41(2):133‐135.
Markle JG, Fish EN. SeXX matters in immunity. Trends Immunol. 2014;35(3):97‐104.
Pasin C, Consiglio CR, Huisman Jana S, et al. Sex and gender in infection and immunity: addressing the bottlenecks from basic science to public health and clinical applications. Royal Soc Open Sci. 2023;10(7): 221628.
Taneja V. Sex hormones determine immune response. Front Immunol. 2018;9:1931.
Moulton VR. Sex hormones in acquired immunity and autoimmune disease. Front Immunol. 2018;9:2279.
Ortona E, Pierdominici M, Rider V. Editorial: Sex hormones and gender differences in immune responses. Front Immunol. 2019;10(1076):444089.
Cunningham M, Gilkeson G. Estrogen receptors in immunity and autoimmunity. Clin Rev Allergy Immunol. 2011;40(1):66‐73.
Furman D, Hejblum BP, Simon N, et al. Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proc Natl Acad Sci U S A. 2014;111(2):869‐874.
Rechtien A, Altfeld M. Sexual dimorphism in HIV‐1 infection. Semin Immunopathol. 2019;41(2):195‐202.
Napravnik S, Poole C, Thomas JC, Eron JJ Jr. Gender difference in HIV RNA levels: a meta‐analysis of published studies. J Acquir Immune Defic Syndr. 2002;31(1):11‐19.
Ruel TD, Zanoni BC, Ssewanyana I, et al. Sex differences in HIV RNA level and CD4 cell percentage during childhood. Clin Infect Dis. 2011;53(6):592‐599.
Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV‐1 RNA levels and progression to AIDS in women and men. New Engl J Med. 2001;344(10):720‐725.
Gandhi M, Bacchetti P, Miotti P, Quinn TC, Veronese F, Greenblatt RM. Does patient Sex affect human immunodeficiency virus levels? Clin Infect Dis. 2002;35(3):313‐322.
Addo MM, Altfeld M. Sex‐based differences in HIV type 1 pathogenesis. J Infect Dis. 2014;209(Suppl 3):S86‐S92.
Gandhi RT, Spritzler J, Chan E, et al. Effect of baseline‐ and treatment‐related factors on immunologic recovery after initiation of antiretroviral therapy in HIV‐1‐positive subjects: results from ACTG 384. JAIDS J Acquired Immune Deficiency Syndromes. 2006;42(4):426‐434.
Meier A, Chang JJ, Chan ES, et al. Sex differences in the toll‐like receptor‐mediated response of plasmacytoid dendritic cells to HIV‐1. Nat Med. 2009;15(8):955‐959.
El‐Badry E, Macharia G, Claiborne D, et al. Better viral control despite higher CD4+ T cell activation during acute HIV‐1 infection in Zambian women is linked to the Sex hormone estradiol. J Virol. 2020;94(16):e00758‐e00720.
Bachmann N, von Siebenthal C, Vongrad V, et al. Determinants of HIV‐1 reservoir size and long‐term dynamics during suppressive ART. Nat Commun. 2019;10(1):3193.
Scully EP, Gandhi M, Johnston R, et al. Sex‐based differences in human immunodeficiency virus type 1 reservoir activity and residual immune activation. J Infect Dis. 2018;219(7):1084‐1094.
Gianella S, Rawlings SA, Dobrowolski C, et al. Sex differences in human immunodeficiency virus persistence and reservoir size during aging. Clin Infect Dis. 2022;75(1):73‐80.
Das B, Dobrowolski C, Luttge B, et al. Estrogen receptor‐1 is a key regulator of HIV‐1 latency that imparts gender‐specific restrictions on the latent reservoir. Proc Natl Acad Sci U S A. 2018;115(33):E7795‐E7804.
Scully EP. Sex differences in HIV infection. Curr HIV/AIDS Rep. 2018;15(2):136‐146.
Morrison CS, Chen PL, Kwok C, et al. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta‐analysis. PLoS Med. 2015;12(1):e1001778.
Ralph LJ, McCoy SI, Shiu K, Padian NS. Hormonal contraceptive use and women's risk of HIV acquisition: a meta‐analysis of observational studies. Lancet Infect Dis. 2015;15(2):181‐189.
Curtis KM, Hannaford PC, Rodriguez MI, Chipato T, Steyn PS, Kiarie JN. Hormonal contraception and HIV acquisition among women: an updated systematic review. BMJ Sexual Reprod Health. 2020;46(1):8‐16.
Ahmed K, Baeten JM, Beksinska M, et al. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open‐label trial. Lancet. 2019;394(10195):303‐313.
Phillips SJ, Curtis KM, Polis CB. Effect of hormonal contraceptive methods on HIV disease progression: a systematic review. Aids. 2013;27(5):787‐794.
Whiteman MK, Jeng G, Samarina A, et al. Associations of hormonal contraceptive use with measures of HIV disease progression and antiretroviral therapy effectiveness. Contraception. 2016;93(1):17‐24.
Baral SD, Poteat T, Strömdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta‐analysis. Lancet Infect Dis. 2013;13(3):214‐222.
Poteat T, Scheim A, Xavier J, Reisner S, Baral S. Global epidemiology of HIV infection and related Syndemics affecting transgender people. JAIDS. J Acquir Immune Defic Syndr. 2016;72:72‐S219.
Nguyen H, Hampel B, Garcia Nuñez D, et al. Identifying and characterizing trans women in the Swiss HIV cohort study as an epidemiologically distinct risk group. Clin Infect Dis. 2021;74(8):1468‐1475.
Stahlman S, Liestman B, Ketende S, et al. Characterizing the HIV risks and potential pathways to HIV infection among transgender women in Côte D'ivoire, Togo and Burkina Faso. J Int AIDS Society. 2016;19(3S2):20774.
Jaspal R, Nambiar KZ, Delpech V, Tariq S. HIV and trans and non‐binary people in the UK. Sex Transm Infect. 2018;94(5):318‐319.
Gianella S, Sonya Haw J, Blumenthal J, Sullivan B, Smith D. The importance of human immunodeficiency virus research for transgender and gender‐nonbinary individuals. Clin Infect Dis. 2018;66(9):1460‐1466.
Jaspal R, Kennedy L, Tariq S. Human immunodeficiency virus and trans women: a literature review. Transgend Health. 2018;3(1):239‐250.
Radix A, Sevelius J, Deutsch MB. Transgender women, hormonal therapy and HIV treatment: a comprehensive review of the literature and recommendations for best practices. J Int AIDS Soc. 2016;19(3 Suppl 2):20810.
Wansom T, Guadamuz TE, Vasan S. Transgender populations and HIV: unique risks, challenges and opportunities. J Virus Erad. 2016;2(2):87‐93.
Braun HM, Candelario J, Hanlon CL, et al. Transgender women living with HIV frequently take antiretroviral therapy and/or feminizing hormone therapy differently than prescribed due to drug–drug interaction concerns. LGBT Health. 2017;4(5):371‐375.
Murray MM, Jensen A, Cieslik T, Cohn SE. Potential risk of drug‐drug interactions with hormonal contraceptives and antiretrovirals: prevalence in women living with HIV. Drugs Context. 2020;9:9‐6.
Scherrer AU, Traytel A, Braun DL, et al. Cohort profile update: the Swiss HIV cohort study (SHCS). Int J Epidemiol. 2022;51(1):33‐4j.
Olink Inflammation 2019 Available from: https://www.olink.com/content/uploads/2019/04/Olink-Inflammation-Validation-Data-v3.0.pdf.
Hile SJ, Feldman MB, Alexy ER, Irvine MK. Recent tobacco smoking is associated with poor HIV medical outcomes among HIV‐infected individuals in New York. AIDS Behav. 2016;20(8):1722‐1729.
Feldman JG, Minkoff H, Schneider MF, et al. Association of Cigarette Smoking with HIV prognosis among women in the HAART era: a report from the Women's interagency HIV study. Am J Public Health. 2006;96(6):1060‐1065.
Muccini C, Crowell TA, Pinyakorn S, et al. Brief report: syphilis incidence and effect on viral load, CD4, and CD4/CD8 ratio in a Thai cohort of predominantly men who have Sex with men living with HIV. JAIDS. J Acquir Immune Defic Syndr. 2021;86(2):219‐223.
Giltay EJ, Fonk JCM, von Blomberg BME, Drexhage HA, Schalkwijk C, Gooren LJG. In vivo effects of Sex steroids on lymphocyte responsiveness and immunoglobulin levels in humans. J Clin Endocrinol Metabol. 2000;85(4):1648‐1657.
Hachfeld A, Atkinson A, Stute P, et al. Women with HIV transitioning through menopause: insights from the Swiss HIV cohort study (SHCS). HIV Med. 2022;23(4):417‐425.
Peckham H, Webb K, Rosser EC, Butler G, Ciurtin C. Gender‐diverse inclusion in immunological research: benefits to science and health. Front Med. 2022;9:909789.
Brodin P, Davis MM. Human immune system variation. Nat Rev Immunol. 2017;17(1):21‐29.
Pulendran B. Systems vaccinology: probing humanity's diverse immune systems with vaccines. Proc Natl Acad Sci. 2014;111(34):12300‐12306.
Lacombe‐Duncan A, Bauer GR, Logie CH, et al. The HIV care Cascade among transgender women with HIV in Canada: a mixed‐methods study. AIDS Patient Care STDS. 2019;33(7):308‐322.
Jäggi T, Jellestad L, Corbisiero S, et al. Gender minority stress and depressive symptoms in transitioned Swiss Transpersons. Biomed Res Int. 2018;2018: 8639263.
Baker KE, Wilson LM, Sharma R, Dukhanin V, McArthur K, Robinson KA. Hormone therapy, mental health, and quality of life among transgender people: a systematic review. J Endocr Soc. 2021;5(4): bvab011.
Hughto JMW, Gunn HA, Rood BA, Pantalone DW. Social and medical gender affirmation experiences are inversely associated with mental health problems in a U.S. non‐probability sample of transgender adults. Arch Sex Behav. 2020;49(7):2635‐2647.
Glass TR, Battegay M, Cavassini M, et al. Longitudinal analysis of patterns and predictors of changes in self‐reported adherence to antiretroviral therapy: Swiss HIV cohort study. JAIDS J Acquir Immune Defic Syndr. 2010;54(2):197‐203.
Nanni MG, Caruso R, Mitchell AJ, Meggiolaro E, Grassi L. Depression in HIV infected patients: a review. Curr Psychiatry Rep. 2014;17(1):530.
Remien RH, Stirratt MJ, Nguyen N, Robbins RN, Pala AN, Mellins CA. Mental health and HIV/AIDS: the need for an integrated response. Aids. 2019;33(9):1411‐1420.
Uthman OA, Magidson JF, Safren SA, Nachega JB. Depression and adherence to antiretroviral therapy in Low‐, middle‐ and high‐income countries: a systematic review and meta‐analysis. Curr HIV/AIDS Rep. 2014;11(3):291‐307.
Summers NA, Huynh TT, Dunn RC, Cross SL, Fuchs CJ. Effects of gender‐affirming hormone therapy on progression along the HIV care continuum in transgender women. Open Forum Infect Dis. 2021;8(9):ofab404. https://doi.org/10.1093/ofid/ofab404
Hachfeld A, Atkinson A, Stute P, et al. Brief report: does menopause transition influence viral suppression and adherence in women living with HIV? JAIDS J Acquir Immune Defic Syndr. 2023;92(5):399‐404.
Wilson R, Spiers A, Ewan J, Johnson P, Jenkins C, Carr S. Effects of high dose oestrogen therapy on circulating inflammatory markers. Maturitas. 2009;62(3):281‐286.